市場調査レポート

商品コード

1653949

特発性肺線維症治療市場規模、シェア、成長分析：薬剤クラス別、投与経路別、作用機序別、流通チャネル別、最終用途別、地域別 - 産業予測 2025～2032年

Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, and Growth Analysis, By Drug Class, By Route of Administration, By Mode of Action, By Distribution Channel, By End-use, By Region - Industry Forecast 2025-2032

出版日: 2025年02月10日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 763,518円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 893,172円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,022,826円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

特発性肺線維症治療市場規模は2023年に46億米ドルと評価され、2024年の49億2,000万米ドルから2032年には83億9,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは6.9％で成長する見通しです。

世界の特発性肺線維症（IPF）治療市場は、主に人口の増加と呼吸器疾患に対する意識の高まりによって、大幅な成長を遂げています。IPFは、呼吸を障害する肺の瘢痕化を特徴とし、肺線維症の主流です。現在の治療法には、ニンテダニブやピルフェニドンといったFDA承認の薬理療法がある一方、進行した患者には肺移植が有効な解決策となっています。近年、研究開発活動が急増し、有望な治療法の革新や新薬候補が生み出されています。さらに、製薬企業と研究機関の戦略的提携が効果的なIPF治療法の開発を後押しし、市場ダイナミクスをさらに活性化させ、患者の治療成果を向上させています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024）

主要企業プロファイル

Boehringer Ingelheim International GmbH（Germany）
Hoffmann-La Roche Ltd.（Switzerland）
AstraZeneca（UK）
Biogen（USA）
FibroGen, Inc.（USA）
Bristol Myers Squibb Company（USA）
GNI Group Ltd.（Japan）
Cipla Inc.（India）
Amgen Inc.（USA）
Mission Therapeutics（UK）
Galapagos NV（Belgium）
Promedior, Inc.（USA）
Zai Lab Limited（China）
Pliant Therapeutics, Inc.（USA）
Kadmon Holdings, Inc.（USA）
Genentech, Inc.（USA）
Sanofi（France）
Merck & Co., Inc.（USA）
Novartis AG（Switzerland）
United Therapeutics Corporation（USA）

結論と提言

Product Code: SQMIG35I2261

Idiopathic Pulmonary Fibrosis Treatment Market size was valued at USD 4.6 billion in 2023 and is poised to grow from USD 4.92 billion in 2024 to USD 8.39 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The global idiopathic pulmonary fibrosis (IPF) treatment market has seen substantial growth, primarily driven by an increasing population and heightened awareness of respiratory diseases. IPF, characterized by lung scarring that impairs breathing, is the predominant form of pulmonary fibrosis. Current treatment options include FDA-approved pharmacological therapies like Nintedanib and Pirfenidone, while lung transplantation remains a viable solution for patients in advanced stages of the disease. Recent years have witnessed a surge in R&D activities, resulting in promising therapeutic innovations and new drug candidates. Moreover, strategic collaborations between pharmaceutical companies and research institutions are propelling the development of effective IPF treatments, further invigorating market dynamics and enhancing patient care outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Idiopathic Pulmonary Fibrosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Idiopathic Pulmonary Fibrosis Treatment Market Segments Analysis

Global Idiopathic Pulmonary Fibrosis Treatment Market is segmented by Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use and region. Based on Drug Class, the market is segmented into Pirfenidone, Nintedanib and Others. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Mode of Action, the market is segmented into Antifibrotic Agents, Tyrosine Kinase Inhibitors and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on End-use, the market is segmented into Hospitals, Clinics and Homecare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Idiopathic Pulmonary Fibrosis Treatment Market

A significant factor propelling the Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market is the growing incidence of IPF, especially among the elderly demographic. As the disease becomes more common worldwide, there is an escalating demand for effective treatment modalities. This increase in diagnosed cases highlights the urgent need for pharmaceutical solutions and therapies that can not only decelerate the progression of the disease but also enhance the overall quality of life for patients. Consequently, the continual rise in the prevalence of IPF serves as a vital driver for the expansion and innovation within this treatment market.

Restraints in the Idiopathic Pulmonary Fibrosis Treatment Market

A significant challenge facing the idiopathic pulmonary fibrosis (IPF) treatment market is the prohibitive cost associated with therapies. The expenses tied to medications and diagnostic procedures can be substantial, potentially restricting access to essential treatments, particularly in areas where healthcare resources are scarce or insurance coverage is insufficient. This financial barrier can hinder the availability and affordability of effective therapeutic options, ultimately affecting patient outcomes and limiting the overall growth potential of the IPF treatment market in various regions, particularly those with less developed healthcare infrastructure. Addressing these cost-related issues is crucial for improving patient access to necessary care.

Market Trends of the Idiopathic Pulmonary Fibrosis Treatment Market

The idiopathic pulmonary fibrosis (IPF) treatment market is witnessing a significant shift towards personalized medicine and precision therapeutics, reflecting a broader trend in healthcare. As research progresses, the emphasis has moved from understanding the disease's pathogenesis to developing tailored treatment strategies aimed at individual patient profiles. Notable advancements in pharmacotherapy, particularly with the introduction of Nintedanib and Pirfenidone, have demonstrated efficacy in slowing the decline in forced vital capacity (FVC) and improving patient quality of life. This growing focus on individualized treatment plans is poised to drive market growth, as stakeholders aim to enhance therapeutic outcomes and optimize patient care in IPF management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Patent Analysis

Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Pirfenidone
Nintedanib
Others

Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Oral
Injectable

Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Mode of Action & CAGR (2025-2032)

Market Overview
Antifibrotic Agents
Tyrosine Kinase Inhibitors
Others

Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Idiopathic Pulmonary Fibrosis Treatment Market Size by End-use & CAGR (2025-2032)

Market Overview
Hospitals
Clinics
Homecare Settings

Global Idiopathic Pulmonary Fibrosis Treatment Market Size & CAGR (2025-2032)

North America (Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use)
- US
- Canada
Europe (Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Route of Administration, Mode of Action, Distribution Channel, End-use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FibroGen, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GNI Group Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Inc. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mission Therapeutics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Galapagos NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Promedior, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zai Lab Limited (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pliant Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kadmon Holdings, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
United Therapeutics Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

特発性肺線維症治療市場規模、シェア、成長分析：薬剤クラス別、投与経路別、作用機序別、流通チャネル別、最終用途別、地域別 - 産業予測 2025～2032年

Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, and Growth Analysis, By Drug Class, By Route of Administration, By Mode of Action, By Distribution Channel, By End-use, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

特発性肺線維症治療市場規模：薬剤クラス別& CAGR（2025-2032）

特発性肺線維症治療市場規模：投与経路別& CAGR（2025-2032）

特発性肺線維症治療市場規模：作用機序別& CAGR（2025-2032）

特発性肺線維症治療市場規模：流通チャネル別& CAGR（2025-2032）

特発性肺線維症治療市場規模：最終用途別& CAGR（2025-2032）

特発性肺線維症治療市場規模：地域別& CAGR（2025-2032）